A marketing authorisation is only the starting line for a biosimilar. The harder contest is uptake: convincing payers, procurement bodies and prescribers to actually switch. With EU regulators streamlining biosimilar development, more products are on the way \u2014 and market access, not approval, is increasingly where launches are won or lost.<\/p>\n
In most European systems, hospital biologics are bought through tenders. Award criteria, contract length and whether a market is single- or multi-winner shape how quickly a biosimilar gains share. Understanding the tender calendar and the rules of each procurement body is often more decisive than the headline price, because a well-timed, well-structured bid can capture volume that a simple discount cannot.<\/p>\n
The EMA and HMA position that EU-approved biosimilars are interchangeable removes a major clinical objection to switching stable patients. But translating that scientific position into practice still depends on national policy: some Member States actively encourage or even mandate substitution, while others leave it to the prescriber. A market-access plan has to be built around the specific substitution and switching rules of each target country.<\/p>\n
Payers rarely need another efficacy trial; they need to understand budget impact. Cost-minimisation analyses, budget-impact models and clear real-world switching data are the currency of biosimilar access. The value story is usually about equivalent outcomes at a lower total cost of care, backed by evidence that switching is safe and manageable in routine practice.<\/p>\n
In Greece, reimbursement and pricing sit within the EOPYY framework, the official Price Bulletin and the clawback and rebate mechanisms that shape the real economics of every product. Biosimilars are a central tool for controlling biologics expenditure, but sponsors need a pricing and access strategy that anticipates clawback exposure and aligns with national uptake targets rather than treating Greece as an afterthought.<\/p>\n
PQRA builds market-access and reimbursement strategies for biosimilars entering Greece and the EU \u2014 from budget-impact models and payer evidence to pricing and tender support. If approval is in sight, we can help you plan the access route that turns it into real patient uptake.<\/em><\/p>","protected":false},"excerpt":{"rendered":" Approval is only the start. How tenders, interchangeability policy and payer evidence decide whether a biosimilar actually gains share.<\/p>","protected":false},"author":1,"featured_media":421,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[9,13],"tags":[],"class_list":["post-422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-knowledge-base","category-market-access"],"yoast_head":"\n